Analysts See $-0.21 EPS for Conformis, Inc. (CFMS)

July 11, 2018 - By Vernon Prom

Conformis, Inc. (NASDAQ:CFMS) Logo

Analysts expect Conformis, Inc. (NASDAQ:CFMS) to report $-0.21 EPS on August, 2.They anticipate $0.07 EPS change or 25.00 % from last quarter’s $-0.28 EPS. After having $-0.22 EPS previously, Conformis, Inc.’s analysts see -4.55 % EPS growth. The stock decreased 5.13% or $0.06 during the last trading session, reaching $1.11. About 403,602 shares traded. Conformis, Inc. (NASDAQ:CFMS) has declined 70.00% since July 12, 2017 and is downtrending. It has underperformed by 82.57% the S&P500.

Conformis, Inc. (NASDAQ:CFMS) Ratings Coverage

Among 2 analysts covering ConforMIS (NASDAQ:CFMS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ConforMIS had 3 analyst reports since February 8, 2018 according to SRatingsIntel. The rating was maintained by Canaccord Genuity with “Hold” on Thursday, February 8. The stock has “Buy” rating by Canaccord Genuity on Tuesday, April 10.

ConforMIS, Inc., a medical technology company, develops, makes, and sells customized joint replacement implants. The company has market cap of $67.61 million. The firm offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee, as well as provides iJigs, customized single-use patient-specific instruments. It currently has negative earnings. It is also developing iTotal Hip, a customized total hip replacement implant.

Another recent and important Conformis, Inc. (NASDAQ:CFMS) news was published by which published an article titled: “Peer Reviewed Results: Conformis Patient Specific iTotal CR Achieves Better Rotational Alignment and Tibial Fit …” on June 25, 2018.

Conformis, Inc. (NASDAQ:CFMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.